체외진단 효소 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 효소 유형별, 질환 유형별, 기술 유형별, 최종 사용별, 지역별, 경쟁(2021-2031년)

The Global In-vitro Diagnostics Enzymes Market is projected to expand from USD 3.63 Billion in 2025 to USD 5.74 Billion by 2031, registering a CAGR of 7.94%. These enzymes, which include specialized biocatalysts like nucleases and polymerases, are essential for facilitating the specific biochemical reactions required to detect biomarkers in biological specimens. This market expansion is fundamentally driven by the rising global incidence of chronic and infectious diseases, which creates a sustained demand for high-volume clinical testing. Additionally, the growing geriatric population and the healthcare sector's focus on early disease detection provide a strong foundation for the increasing consumption of these vital reagents.

Conversely, the industry confronts substantial hurdles related to strict regulatory environments that can hamper supply chain efficiency and commercialization efforts. Rigorous compliance requirements often establish obstacles for manufacturers introducing new diagnostic products, subsequently retarding the procurement of raw materials. According to the Association of British HealthTech Industries, 82% of the sector was affected by regulatory uncertainty in 2024, leading to quantifiable delays in market entry for innovations. These barriers within the downstream diagnostics sector directly limit the growth potential of the global enzymes market.

Market Driver

Innovations in Next-Generation Sequencing (NGS) and molecular diagnostics are transforming the enzyme industry by demanding specialized modification reagents and high-fidelity polymerases. As laboratories adopt intricate genomic workflows for genetic disorder screening and oncology, the use of these biocatalysts in sequencing protocols and library preparation has increased significantly. This dependence on high-volume reagent consumption secures a recurring revenue source for suppliers, separate from one-time equipment sales. For instance, Qiagen N.V. reported in February 2024 that its non-COVID portfolio expanded by 8% at constant exchange rates during 2023, with consumables-including these essential enzymatic kits-representing over 85% of total net sales.

Simultaneously, the proliferation of Point-of-Care (PoC) Diagnostic Testing is extending market reach beyond centralized labs, fueling the need for durable, thermostable enzymes suitable for decentralized environments. This trend toward rapid, near-patient testing necessitates enzymes that retain sensitivity and stability without cold-chain infrastructure, promoting advancements in air-dried and lyophilized formats. Illustrating this demand, Danaher Corporation reported in January 2024 that its subsidiary Cepheid achieved roughly $650 million in respiratory testing revenue in Q4 2023, driven by the strong adoption of rapid molecular assays. To sustain such vast testing networks, F. Hoffmann-La Roche Ltd noted in 2024 that it supplied 29 billion diagnostic tests globally the prior year, underscoring the massive quantity of enzymes needed for global diagnostics.

Market Challenge

Strict regulatory structures pose a significant obstacle to the advancement of the Global In-vitro Diagnostics Enzymes Market. Because biocatalysts are critical elements of diagnostic kits, their market success is tied directly to the regulatory clearance of the finished diagnostic devices. When manufacturers encounter rigorous compliance mandates and extended approval procedures, development schedules for new diagnostic tools are inevitably delayed. This regulatory friction interrupts the supply chain, forcing enzyme providers to align their production with the unpredictable schedules of diagnostic kit manufacturers, ultimately leading to stalled demand for these key raw materials and reduced revenue for enzyme producers.

The consequences of these bottlenecks are visible as companies deprioritize markets with complicated compliance landscapes. The heavy resource requirements needed to meet new standards have led to a contraction in market entry and innovation. According to MedTech Europe, the preference for the European Union as a primary launch region for major in-vitro diagnostic manufacturers fell by 40% in 2024 due to the complexity of emerging regulatory requirements. This marked decline in new product introductions correlates directly with reduced enzyme usage, as fewer diagnostic tests achieve commercialization to drive biocatalyst uptake.

Market Trends

The incorporation of specialized enzymes into liquid biopsy workflows is becoming a major trend, spurring demand for high-sensitivity biocatalysts that can detect circulating tumor DNA (ctDNA) with high precision. In contrast to standard tissue biopsies, these non-invasive tests utilize enzymes like hyper-active polymerases and engineered ligases to effectively analyze low-input biological samples for molecular residual disease (MRD). This evolution requires the ongoing creation of reagents that enhance signal amplification and reduce background noise in complex screening procedures. Exact Sciences Corp. highlighted this in January 2025, projecting full-year 2024 revenue of $2.76 billion and announcing the upcoming launch of Oncodetect, an MRD test that emphasizes the vital function of specialized enzymatic workflows in cancer diagnostics.

Concurrently, the increasing application of enzymes in Digital PCR (dPCR) systems is carving out a niche market dedicated to absolute quantification without relying on standard curves. This technology is gaining traction in critical clinical areas, such as viral load measurement and transplant monitoring, where accurate copy number variation analysis is required. The growth of dPCR platforms generates a specific need for thermostable enzymes and partitioning-compatible master mixes that function within nanowells or microfluidic droplets. In February 2025, Bio-Rad Laboratories, Inc. announced a strategic investment in Oncocyte to commercialize transplant monitoring assays using the QX600 Droplet Digital PCR system, illustrating the growing integration of enzymatic reagents in advanced digital quantification tools.

Key Market Players

• Merck KGaA
• Codexis, Inc.
• F. Hoffmann-La Roche Ltd.
• Amano Enzyme Inc.
• Advanced Enzymes Technologies Ltd.
• Biocatalysts Ltd.
• Amicogen Co., Ltd.
• Dyadic International Inc
• Baduhenna Topco Limited
• Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global In-vitro Diagnostics Enzymes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In-vitro Diagnostics Enzymes Market, By Enzyme Type

• Polymerase & Transcriptase
• Proteases

In-vitro Diagnostics Enzymes Market, By Disease Type

• Infectious disease
• Diabetes
• Oncology
• Cardiology
• Nephrology
• Autoimmune diseases
• Others

In-vitro Diagnostics Enzymes Market, By Technology Type

• Histology Assays
• Molecular Diagnostics
• Clinical Chemistry

In-vitro Diagnostics Enzymes Market, By End-Use

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

In-vitro Diagnostics Enzymes Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global In-vitro Diagnostics Enzymes Market.

Available Customizations:

Global In-vitro Diagnostics Enzymes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global In-vitro Diagnostics Enzymes Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Enzyme Type (Polymerase & Transcriptase, Proteases)
  • 5.2.2. By Disease Type (Infectious disease, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune diseases, Others)
  • 5.2.3. By Technology Type (Histology Assays, Molecular Diagnostics, Clinical Chemistry)
  • 5.2.4. By End-Use (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America In-vitro Diagnostics Enzymes Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Enzyme Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Technology Type
  • 6.2.4. By End-Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States In-vitro Diagnostics Enzymes Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Enzyme Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Technology Type
      • 6.3.1.2.4. By End-Use
  • 6.3.2. Canada In-vitro Diagnostics Enzymes Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Enzyme Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Technology Type
      • 6.3.2.2.4. By End-Use
  • 6.3.3. Mexico In-vitro Diagnostics Enzymes Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Enzyme Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Technology Type
      • 6.3.3.2.4. By End-Use

7. Europe In-vitro Diagnostics Enzymes Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Enzyme Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Technology Type
  • 7.2.4. By End-Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany In-vitro Diagnostics Enzymes Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Enzyme Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Technology Type
      • 7.3.1.2.4. By End-Use
  • 7.3.2. France In-vitro Diagnostics Enzymes Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Enzyme Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Technology Type
      • 7.3.2.2.4. By End-Use
  • 7.3.3. United Kingdom In-vitro Diagnostics Enzymes Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Enzyme Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Technology Type
      • 7.3.3.2.4. By End-Use
  • 7.3.4. Italy In-vitro Diagnostics Enzymes Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Enzyme Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Technology Type
      • 7.3.4.2.4. By End-Use
  • 7.3.5. Spain In-vitro Diagnostics Enzymes Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Enzyme Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Technology Type
      • 7.3.5.2.4. By End-Use

8. Asia Pacific In-vitro Diagnostics Enzymes Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Enzyme Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Technology Type
  • 8.2.4. By End-Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China In-vitro Diagnostics Enzymes Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Enzyme Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Technology Type
      • 8.3.1.2.4. By End-Use
  • 8.3.2. India In-vitro Diagnostics Enzymes Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Enzyme Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Technology Type
      • 8.3.2.2.4. By End-Use
  • 8.3.3. Japan In-vitro Diagnostics Enzymes Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Enzyme Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Technology Type
      • 8.3.3.2.4. By End-Use
  • 8.3.4. South Korea In-vitro Diagnostics Enzymes Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Enzyme Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By Technology Type
      • 8.3.4.2.4. By End-Use
  • 8.3.5. Australia In-vitro Diagnostics Enzymes Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Enzyme Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By Technology Type
      • 8.3.5.2.4. By End-Use

9. Middle East & Africa In-vitro Diagnostics Enzymes Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Enzyme Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Technology Type
  • 9.2.4. By End-Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia In-vitro Diagnostics Enzymes Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Enzyme Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Technology Type
      • 9.3.1.2.4. By End-Use
  • 9.3.2. UAE In-vitro Diagnostics Enzymes Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Enzyme Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Technology Type
      • 9.3.2.2.4. By End-Use
  • 9.3.3. South Africa In-vitro Diagnostics Enzymes Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Enzyme Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Technology Type
      • 9.3.3.2.4. By End-Use

10. South America In-vitro Diagnostics Enzymes Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Enzyme Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Technology Type
  • 10.2.4. By End-Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil In-vitro Diagnostics Enzymes Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Enzyme Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Technology Type
      • 10.3.1.2.4. By End-Use
  • 10.3.2. Colombia In-vitro Diagnostics Enzymes Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Enzyme Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Technology Type
      • 10.3.2.2.4. By End-Use
  • 10.3.3. Argentina In-vitro Diagnostics Enzymes Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Enzyme Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Technology Type
      • 10.3.3.2.4. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global In-vitro Diagnostics Enzymes Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck KGaA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Codexis, Inc.
• 15.3. F. Hoffmann-La Roche Ltd.
• 15.4. Amano Enzyme Inc.
• 15.5. Advanced Enzymes Technologies Ltd.
• 15.6. Biocatalysts Ltd.
• 15.7. Amicogen Co., Ltd.
• 15.8. Dyadic International Inc
• 15.9. Baduhenna Topco Limited
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer